Skip to content

The effect of Lactobacillus acidophilus e Bifidobacterium lactis on hepatic steatosis and difficulty in insulin action in obese adolescents: A randomized clinical trial

Efficacy of Lactobacillus acidophilus e Bifidobacterium lactis on Nonalcoholic Fatty Liver Disease and insulin resistance in obese adolescents: A randomized clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-9n7kfw
Enrollment
Unknown
Registered
2020-09-30
Start date
2019-05-17
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pediatric Obesity

Interventions

Intervention Group: 14 adolescents from 10 to 19 years old will receive a probiotic mix containing Lactobacillus acidophilus LA-5® and Bifidobacterium lactis BB-12®, containing 1 x 10^9 CFU (Colonies
Dietary supplement
G07.203.300.456.500

Sponsors

Escola Bahiana de Medicina e Saúde Pública
Lead Sponsor
Delphin Medicina DIagnóstica
Collaborator
Centro de Pesquisas Gonçalo Moniz - Fiocruz/BA
Collaborator

Eligibility

Age
10 Years to 19 Years

Inclusion criteria

Inclusion criteria: Adolescents between 10 to 19 years old; Diagnosis of obesity, based on the BMI/age indicator above +2 z scores of the WHO reference curve; Previous ultrasound diagnosis of Non-Alcoholic Fatty Liver Disease; Signature of the Review Board Authorization Form; Previous history of attendance to the service (absence of absences in the previous year); Absence of diabetes mellitus (fasting blood glucose below 100 mg/dl); Living in Salvador or metropolitan urban area;

Exclusion criteria

Exclusion criteria: Presence of endogenous obesity; Presence of psychiatric comorbidity or disease that interferes with weight evolution; Use of medications such as metformin, statins, laxatives, antibiotics, antidepressants, corticosteroids, anxiolytics and / or any other medication that may interfere with the gut microbiota; Be classified as SGA (Small for Gestational Age) at birth;

Design outcomes

Primary

MeasureTime frame
It is expected to find at least a reduction of 15% in liver fat percent obtained by nuclear magnetic resonance (PDFF method - Proton Density Fat Fraction);It is expected to find a reduction in Insulin resistance, quantified by a minimum decrease of 20% in the HOMA-IR index pre- and post-intervention.

Secondary

MeasureTime frame
It is expected to find a reduction of at least 20% in the seric values of AST, ALT and GGT pre- and post-intervention.;It is expected to find a reduction of at least 20% in the ferritin serum levels pre- and post-intervention.;It is expected to find a minimum decrease of 20% in the circulating interleukins levels (tumor necrosis factor-alpha - TNF-alpha, Interleukin 2 and 6 - IL-2 and IL-6) pre- and post-intervention.;It is expected to find a minimum decrease of 20% in the serum levels of adiponectin pre- and post-intervention.

Countries

Brazil

Contacts

Public ContactNey Boa-Sorte

Escola Bahiana de Medicina e Saúde Pública

neyboasorte@bahiana.edu.br+55-71-32768275

Outcome results

None listed

Source: REBEC (via WHO ICTRP)